CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2-...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammed, Amrallah A., Rashied, Hanaa, Elsayed, Fifi Mostafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683209/
https://www.ncbi.nlm.nih.gov/pubmed/31452841
http://dx.doi.org/10.4081/oncol.2019.416
_version_ 1783442039831003136
author Mohammed, Amrallah A.
Rashied, Hanaa
Elsayed, Fifi Mostafa
author_facet Mohammed, Amrallah A.
Rashied, Hanaa
Elsayed, Fifi Mostafa
author_sort Mohammed, Amrallah A.
collection PubMed
description Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation.
format Online
Article
Text
id pubmed-6683209
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-66832092019-08-26 CDK4/6 inhibitors in advanced breast cancer, what is beyond? Mohammed, Amrallah A. Rashied, Hanaa Elsayed, Fifi Mostafa Oncol Rev Review Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation. PAGEPress Publications, Pavia, Italy 2019-07-29 /pmc/articles/PMC6683209/ /pubmed/31452841 http://dx.doi.org/10.4081/oncol.2019.416 Text en ©Copyright: the Author(s), 2019 http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).
spellingShingle Review
Mohammed, Amrallah A.
Rashied, Hanaa
Elsayed, Fifi Mostafa
CDK4/6 inhibitors in advanced breast cancer, what is beyond?
title CDK4/6 inhibitors in advanced breast cancer, what is beyond?
title_full CDK4/6 inhibitors in advanced breast cancer, what is beyond?
title_fullStr CDK4/6 inhibitors in advanced breast cancer, what is beyond?
title_full_unstemmed CDK4/6 inhibitors in advanced breast cancer, what is beyond?
title_short CDK4/6 inhibitors in advanced breast cancer, what is beyond?
title_sort cdk4/6 inhibitors in advanced breast cancer, what is beyond?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683209/
https://www.ncbi.nlm.nih.gov/pubmed/31452841
http://dx.doi.org/10.4081/oncol.2019.416
work_keys_str_mv AT mohammedamrallaha cdk46inhibitorsinadvancedbreastcancerwhatisbeyond
AT rashiedhanaa cdk46inhibitorsinadvancedbreastcancerwhatisbeyond
AT elsayedfifimostafa cdk46inhibitorsinadvancedbreastcancerwhatisbeyond

Ejemplares similares